Cebix hangs it up after raising $50M for diabetes drug

Damian Garde La Jolla, CA's Cebix has quietly closed up shop, Xconomy reports, after its once-promising diabetes candidate failed to hit the mark in Phase IIb. FierceBiotech News

Novo Nordisk’s game-changing oral diabetes drug clears Phase II

Damian Garde Novo Nordisk's new oral diabetes drug measured up to its injected counterpart in a midstage study, promising results the company heralds as a milestone in the field. FierceBiotech ...

Roche boasts new Lucentis approval for retinal damage in diabetes

Carly Helfand Roche now has another approval under its belt for eye drug Lucentis. And it’s in a market it can call its own: Lucentis is the first U.S.-approved treatment for ...

Merck KGaA expands diabetes presence in Middle East with new education program

Emily Wasserman Setting up camp in the Middle East is the trend du jour in Big Pharma, and Merck KGaA is expanding its footprint there by launching its new diabetes education program ...

Novo Nordisk quells diabetes pricing fears with 2015 growth forecast

Tracy Staton Novo Nordisk has made diabetes-minded investors very happy today. Rather than following Sanofi's discouraging announcement of flat sales expectations in the field next ...

Novo Nordisk bets another $130M on diabetes R&D with new Danish hub

Damian Garde Novo Nordisk has broken ground on a new R&D shop in its native Denmark, plotting a $ 130 million project that will expand its wide footprint in diabetes research. FierceBiotech ...

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

Tracy Staton When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing ...

Merck taps celeb chef to deliver diabetes message to Hispanics

Carly Helfand Merck's America's Diabetes Challenge: Get to Your Goals campaign is aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck ...

Lilly, Boehringer win FDA approval for once-rejected diabetes drug

Damian Garde After a manufacturing issue scuttled their first attempt, Eli Lilly and Boehringer Ingelheim have won the FDA's blessing to market their new diabetes drug, a late entrant ...

FDA comes around on Boehringer, Lilly’s diabetes med Jardiance

Carly Helfand The FDA is changing its tune on Jardiance, a Boehringer Ingelheim diabetes med it hasn't been so keen on in the past. After rejecting the drug in the ...

Novo’s blockbuster diabetes combo nears EU approval

Damian Garde A committee of European Medicines Agency advisers is recommending approval for Novo Nordisk's combination of a long-acting insulin and its blockbuster GLP-1 drug Victoza, ...

Cost-conscious payers are eyeing higher prices on diabetes drugs

Tracy Staton A time-honored technique for boosting drug sales is simple: Raise prices. Lately, plenty of drugmakers pressed by patent-cliff losses have done just that. But some notable ...
Page 2 of 812345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS